Correlation of CD34+ cell dose with engraftment kinetics

November 11, 2010

CD34 is the most frequently currently used marker for estimation of engraftment success and suitability of the graft in hematology-oncology. Remarkably, almost everyone in the clinic associates this marker with hematopoietic stem cell (HSC) activity and function. Indeed, there is an HSC population within CD34+ cells, but a very tiny one. Recently, Weissman group has [...]

Read the full article →

The value of stem cells in commercial cell therapeutic products

October 29, 2010

We are all so excited about the possibility of using stem cells for therapy. There is no doubt, stem cells have a huge therapeutic potential. But potential could be very different from reality. I was trying to find any commercial stem cell product available on the market, but didn’t succeed in my search. Well, maybe [...]

Read the full article →

Top 5 stem cell retractions

October 21, 2010

News about scandalous stem cell paper retraction from Nature journal blew up in the mass media last week. This event reminded me about some other “big stem cell retractions” in the past. I’ve picked five of the most interesting cases in my opinion and to share with you today. All of them were “big”, scandalous [...]

Read the full article →

Trends in hematopoietic stem cell expansion 2010

October 12, 2010

As many of you know, I’m highly interested in this topic and proposed a thread “Do we really need hematopoietic stem cell expansion for clinical use?”. I’ve got only one comment on the blog, but 117 comments on LinkedIn (International Society for Stem Cell Research group) and about 10 comments in Google Buzz. The discussion [...]

Read the full article →

Trends in Cell Therapy 2010

September 30, 2010

I’d like to share with you the presentation that I gave 3 days ago in Moscow. I was invited by conference organizers and it was great small event! CellTherapyTrends10 View more presentations from nanog.

Read the full article →

Hematopoietic stem cell heterogeneity and assay-based definition

September 17, 2010

This is re-blog from Stem Cell Assays I’d like to share the presentation that I gave today for journal club. The paper for journal club that I picked – Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. HSC_heterogeneity_definition View more presentations from nanog.

Read the full article →

Stem cell autopsy: Two ALS cases of neurotransplantation in China

September 7, 2010

I continue to pick some reported findings from autopsies and biopsies of patients underwent cell therapy procedures. Today, I’d like to share with you the story of two fatal cases of ALS patients, traveled for cell therapy to Beijing (China). The large number of patients with neurodegenerative disorders (stroke, ataxia, ALS, cerebral palsy…) traveled to [...]

Read the full article →

Stem cell tourism – from anecdotal and speculative cases to observational studies.

August 30, 2010

Stem cell tourism is here. It exists and, apparently, it’s a good business. But does it really help patients? What are the results and long-term outcomes? Professionals (physicians and scientists) are staying skeptical and referring to lack of any reported data about “stem cell treatments” abroad. There are stories of many cases you can read [...]

Read the full article →

Cell therapy activity statistics

August 20, 2010

I’d like to highlight the importance of collecting data dedicated to cell therapy activity. First of all, analysis of scientific literature, indexed in PubMed can capture very small part of all activities in clinical cell therapy field. Collecting such data will allow us to define some trends, estimate potential market and navigate the community to [...]

Read the full article →

Safety of mismatched cord blood transplantation in regenerative medicine

August 11, 2010

Many people predict that unrelated allogeneic cord blood (CB) cell transplantation could be “the next big thing” in regenerative medicine. A few obvious questions arise here: 1. Can we transplant HLA-mismatched CB cells into the patient with degenerative disease without fear of adverse immune reactions such as graft-versus-host (GVH) and host-mediated immune clearance? How many [...]

Read the full article →

← Previous Entries

Next Entries →